

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Fluphenazine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, which is approved by the U.S. Food and Drug Administration (USFDA).
Product Name : Fluphenazine Hydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Fluphenazine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluphenazine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
Details : Fluphenazine hydrochloride Tablets are a generic version of the brand product, Prolixin. Company has launched Fluphenazine Hydrochloride Tablets, USP in four strengths, 1 mg, 2.5 mg, 5 mg, and 10 mg.
Product Name : Prolixin-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Fluphenazine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable



